As proposed yesterday by its Advisory Committee on Immunization Practices, the Centers for Disease Control and Prevention recommends that starting this fall all infants under 8 months old receive one dose of the new long-acting monoclonal antibody nirsevimab to prevent respiratory syncytial virus, and that certain infants 8-19 months old at risk for severe disease receive one dose in their second RSV season. The Food and Drug Administration last month approved the product for use in these age groups. An estimated 58,000 to 80,000 U.S. children under age 5, mostly infants, are hospitalized each year due to RSV. 

“RSV is the leading cause of hospitalizations for infants and older babies at higher risk and today we have taken an important step to make this life saving product available,” said CDC director Mandy Cohen, M.D.
 

Related News Articles

Headline
AHA May 23 submitted recommendations to the Department of Justice and Federal Trade Commission in response to the agencies’ requests for information on…
Headline
The Department of Health and Human Services May 13 announced a 60-day public comment period opened for stakeholders regarding its request for information to…
Headline
The Centers for Medicare & Medicaid Services today released a notice seeking public comment on the collection of information request regarding the State…
Headline
The Trump administration yesterday released executive orders on reducing anti-competitive regulatory barriers and repealing certain regulations deemed unlawful…
Headline
The Office of Management and Budget April 9 released a notice seeking public input on rules to potentially be rescinded, requesting detailed reasons…
Headline
The Centers for Disease Control and Prevention Dec. 18 announced that a patient in Louisiana was hospitalized with a severe case of H5N1 bird flu, the first…